Indaptus Therapeutics, Inc.
INDPIndaptus Therapeutics, Inc. in brief
Indaptus Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $513 M on 30 October 2026, which makes it the 12,431st largest listed company in the world and the 2,510th largest in the USA on this site. Junyi Dai is its chief executive. Its shares trade under the symbol INDP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Indaptus Therapeutics, Inc.
We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity in preclinical models, including durable anti-tumor response synergy observed with each of four different classes of existing agents, including NSAIDs, checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology was associated with induction of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting a tumor antigen in preclinical models. In 2023, we initiated a Phase 1 clinical trial with our lead clinical candidate, Decoy20, in patients with advanced solid tumors where currently approved therapies have failed. In May 2025, we decided to conclude enrollment in the dosing of Decoy20 as a monotherapy and focus on the combination study of Decoy20 with BeOne’s anti-PD-1 antibody, Tislelizumab for the treatment of participants with advanced solid tumors, or the Combination Study. As of the date of this Annual Report on Form 10-K, we have discontinued further enrollment in the Combination Study and there are no participants remaining in the study. We do not have any current plans to initiate a new clinical trial.
From the company's annual report filed with the US SEC: read the report
Indaptus Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Indaptus Therapeutics, Inc.Formerly Intec Parent Inc..
Events of Indaptus Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,954 (Jan 2022) · #5,472 (Dec 2022) · #4,432 (Jan 2024) · #2,455 (Mar 2026) · #3,261 (Aug 2026) · #2,730 (Oct 2026) · #2,513 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 162.9×
- Free cash flow yield
- -2.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -661.9%
- Liabilities / assets
- 66.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-20M | $-21M | — |
| Dec 2024 | — | — | $-15M | $-15M | — |
| Dec 2023 | — | — | $-16M | $-15M | — |
| Dec 2022 | — | — | $-15M | $-14M | — |
| Dec 2021 | — | — | $-8M | $-8M | — |
| Dec 2020 | — | — | $-4M | $-4M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-15M | — | — | $-21.58 | — |
| Dec 2024 | $-12M | — | — | $-44.96 | — |
| Dec 2023 | $-13M | — | — | $-1.83 | — |
| Dec 2022 | $-13M | — | — | $-1.73 | — |
| Dec 2021 | $-11M | $0M | $-11M | $-1.89 | — |
| Dec 2020 | $-3M | — | — | $-1.84 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 20, 20268-KCurrent reportOther events
- Sep 30, 20268-KCurrent reportMaterial agreement
- Sep 10, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Sep 8, 20268-K/ACurrent report (amended)Material agreement
- Sep 4, 20268-KCurrent reportDirectors or officers changed
- Sep 1, 20268-KCurrent reportMaterial agreement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations · Shareholder vote
- Jul 16, 2026DEF 14AProxy statement
- Jun 24, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Jun 5, 20268-KCurrent reportDirectors or officers changed
- May 15, 202610-QQuarterly report · period to Mar 2026
Official filings of Indaptus Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-20 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $9 M
- Total liabilities
- $6 M
- Total equity
- $3 M
As of December-2025
Top 21 institutional investors in Indaptus Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 195,620 | +139,150 (+246.41%) | 0.15% | $0 M | Nov 6, 2026 |
| 2 | Vanguard Capital Management LLC | 135,978 | +102,326 (+304.07%) | 0.10% | $0 M | Nov 13, 2026 |
| 3 | Jane Street Group, LLC | 86,484 | +32,673 (+60.72%) | 0.06% | $0 M | Nov 12, 2026 |
| 4 | UBS Group AG | 83,363 | +82,885 (+17339.96%) | 0.06% | $0 M | Nov 10, 2026 |
| 5 | Marshall Wace, LLP | 77,847 | New | 0.06% | $0 M | Nov 13, 2026 |
| 6 | Millennium Management LLC | 72,073 | +60,487 (+522.07%) | 0.05% | $0 M | Nov 16, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 65,315 | +51,348 (+367.64%) | 0.05% | $0 M | Nov 13, 2026 |
| 8 | State Street Corp | 63,866 | New | 0.05% | $0 M | Nov 12, 2026 |
| 9 | Virtu Financial LLC | 34,659 | New | 0.03% | $0 M | Nov 17, 2026 |
| 10 | Jump Financial, LLC | 27,662 | New | 0.02% | $0 M | Nov 13, 2026 |
| 11 | Northern Trust Corp | 27,227 | New | 0.02% | $0 M | Nov 16, 2026 |
| 12 | ExodusPoint Capital Management, LP | 19,884 | New | 0.01% | $0 M | Nov 16, 2026 |
| 13 | Qube Research & Technologies Ltd | 14,688 | New | 0.01% | $0 M | Nov 13, 2026 |
| 14 | Goldman Sachs Group Inc | 14,143 | New | 0.01% | $0 M | Nov 16, 2026 |
| 15 | Barclays PLC | 13,723 | New | 0.01% | $0 M | Nov 6, 2026 |
| 16 | Balyasny Asset Management L.P. | 12,708 | New | 0.01% | $0 M | Nov 16, 2026 |
| 17 | Morgan Stanley | 1,263 | -7,673 (-85.87%) | 0.00% | $0 M | Nov 13, 2026 |
| 18 | Jpmorgan Chase & Co | 28 | New | 0.00% | $0 M | Nov 12, 2026 |
| 19 | SBI Securities Co., Ltd. | 17 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 20 | Caitong International Asset Management Co., Ltd | 2 | New | 0.00% | $0 M | Oct 29, 2026 |
| 21 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Indaptus Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 17,640 | $0 M | 0.01% | <0.01% | +118% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 9,142 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 3,929 | $0 M | <0.01% | <0.01% | +676% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 462 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Indaptus Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Avraham Ben-TzviDirector | Grant or award | +25,000 | — | — | 25,100 | Form 4 |
| filed | Nir SassiChief Financial Officer | Grant or award | +26,758 | $2.030 | $54 K | 26,758 | Form 4 |
| filed | Jeffrey A. MecklerCo-Chief Executive Officer, Director, 10% owner | Grant or award | +216,617 | $2.030 | $440 K | 229,929 | Form 4 |
| filed | Walt Addison LinscottChief Operating Officer | Grant or award | +54,421 | $2.030 | $110 K | 54,426 | Form 4 |
| filed | Michael James NewmanCSO and Director, Director | Grant or award | +52,204 | $2.030 | $106 K | 101,074 | Form 4 |
| filed | Jeffrey A. MecklerChief Executive Officer, Director | Grant or award | +6,068 | $8.300 | $50 K | 13,312 | Form 4 |
| filed | Jeffrey A. MecklerCEO and Director, Director | Grant or award | +42,553 | $1.180 | $50 K | 202,859 | Form 4 |
| filed | Jeffrey A. MecklerCEO and Director, Director | Grant or award | +84,932 | $1.830 | $155 K | 160,306 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Indaptus Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-06-04 16:47 UTC, code LUDP, resumed 16:57 UTC
- 2025-10-07 15:32 UTC, code LUDP, resumed 15:37 UTC
- 2025-10-07 15:04 UTC, code LUDP, resumed 15:09 UTC
- 2025-10-07 14:11 UTC, code LUDP, resumed 14:16 UTC
- 2025-10-07 14:00 UTC, code LUDP, resumed 14:10 UTC
Fails to deliver
- : 162 shares at $3.34
- : 1,094 shares at $3.33
- : 12,077 shares at $3.16
- : 444 shares at $2.99
- : 1,883 shares at $3.16
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Indaptus Therapeutics, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median162.9×Price to book 162.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-2.2%Free cash flow is -2.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-21.58 vs -44.96Diluted EPS -21.58 in fiscal 2025 against -44.96 the year before (report's currency).
- ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$4 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-588.1%-588.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.51 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year189.2%Diluted shares up 189.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Indaptus Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 9,341+28.8%— | 7,251−4.9%— | 7,622+20.5%— | 6,325+151%— | 2,523−5.0%— | 2,655—— | |
| General and administrative | 10,493+29.3%— | 8,115−7.3%— | 8,757+2.0%— | 8,586+64.9%— | 5,206+451%— | 944—— | |
| Operating expenses | 19,834+29.1%— | 15,366−6.2%— | 16,378+9.8%— | 14,911+92.9%— | 7,729+115%— | 3,599—— | |
| Operating income | −19,834—— | −15,366—— | −16,378—— | −14,911—— | −7,729—— | −3,599—— | |
| Other non-operating income (expense) | — | 344−64.0%— | 955+62.4%— | 588+3219%— | 18+17.3%— | 15—— | |
| Income before tax | −20,847—— | −15,020—— | — | — | — | — | |
| Income tax | 1.7+0.9%— | 1.7−30.6%— | 2.5+8067%— | 0.0−98.2%— | 1.7+106%— | 0.8—— | |
| Net income attributable to shareholders | −20,849—— | −15,022—— | −15,423—— | −14,323—— | −7,711—— | −3,584—— | |
| Earnings per share, basic | -21.58—— | -44.96r-1.61—— | -1.83—— | -1.73—— | -1.89—— | -1.84—— | |
| Earnings per share, diluted | -21.58—— | -44.96r-1.61—— | -1.83—— | -1.73—— | -1.89—— | -1.84—— | |
| Shares, weighted average (basic) | 1.0+189%— | 0.3r9.4−96.0%— | 8.4+1.7%— | 8.3+102%— | 4.1—— | — | |
| Shares, weighted average (diluted) | 1.0+189%— | 0.3r9.4−96.0%— | 8.4+1.7%— | 8.3+102%— | 4.1+110%— | 1.9—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 8,508+47.0%91.4% | 5,787−56.7%78.9% | 13,362+38.8%89.5% | 9,627−75.4%34.3% | 39,132+2290%96.4% | 1,637r14,671—92.1% | |
| Short-term investments | — | — | — | 16,806—59.9% | — | — | |
| Other current assets | 803−3.5%8.6% | 832+31.3%11.3% | 633−22.0%4.2% | 811−26.7%2.9% | 1,107+1071%2.7% | 95r297—5.3% | |
| Current assets | 9,310+40.7%100% | 6,618−52.7%90.2% | 13,995−48.6%93.8% | 27,244−32.5%97.1% | 40,387+2232%99.5% | 1,732r14,968—97.4% | |
| Property, plant and equipment | — | — | 0.7−63.6%0.0% | 2.0−46.9%0.0% | 3.8+182%0.0% | 1.3r1,394—0.1% | |
| Right-of-use (leased) assets | — | 82−52.6%1.1% | 173+118%1.2% | 79−53.1%0.3% | 169−79.3%0.4% | 817—46.0% | |
| Non-current assets | — | 720−22.4%9.8% | 929+13.3%6.2% | 820+333%2.9% | 189+314%0.5% | 46r5,928—2.6% | |
| Total assets | 9,310+26.9%100% | 7,339−50.8%100% | 14,924−46.8%100% | 28,064−30.8%100% | 40,577+2182%100% | 1,778r20,896—100% | |
| Accounts payable | 544−37.5%5.8% | 870+8.0%11.9% | 806−41.5%5.4% | 1,378−45.7%4.9% | 2,540r2,638+1529%6.3% | 156r368—8.8% | |
| Current liabilities | 6,159+81.5%66.1% | 3,394+22.3%46.2% | 2,774−19.2%18.6% | 3,433−25.4%12.2% | 4,604+128%11.3% | 2,015r5,334—113% | |
| Lease liabilities (non-current) | — | — | 73—0.5% | — | 73−78.4%0.2% | 338—19.0% | |
| Non-current liabilities | — | — | 73—0.5% | — | 73−92.9%0.2% | 1,029—57.9% | |
| Total liabilities | 6,159+81.5%66.1% | 3,394+19.2%46.2% | 2,847−17.1%19.1% | 3,433−26.6%12.2% | 4,677+132%11.5% | 2,015r6,363—113% | |
| Retained earnings | −81,288—−873% | −60,439—−824% | −45,417—−304% | −29,994—−107% | −15,671—−38.6% | −7,960r−203,551—−448% | |
| Shareholders' equity | 3,152−20.1%33.9% | 3,945−67.3%53.8% | 12,076−51.0%80.9% | 24,630−31.4%87.8% | 35,900—88.5% | −238r14,533—−13.4% | |
| Total liabilities and equity | 9,310+26.9%100% | 7,339−50.8%100% | 14,924−46.8%100% | 28,064−30.8%100% | 40,577+2182%100% | 1,778r20,896—100% | |
| Shares outstanding | 2.2+405%— | 0.4r12−94.9%— | 8.40.0%— | 8.4+1.7%— | 8.3+325%— | 1.9r1.1—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 1,358−41.1%— | 2,306−22.3%— | 2,966+0.3%— | 2,957+95.8%— | 1,510+979%— | 140—— | |
| Cash from operating activities | −14,823—— | −12,323—— | −13,405—— | −13,078—— | −11,291—— | −3,325—— | |
| Capital expenditure | — | — | — | — | −3.9—— | — | |
| Cash from investing activities | — | — | 17,141—— | −16,427−3769%— | 448—— | — | |
| Shares issued | 6,397+16.1%— | 5,511—— | — | — | — | — | |
| Cash from financing activities | 17,544+270%— | 4,748—— | — | — | 48,337+4056%— | 1,163—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 3,971−55.8%— | 271−82.1%— | 363−83.2%— | 491−82.5%— | 2,845*+14.7%— | 1,518+3.5%— | 2,167+26.4%— | 2,811+76.7%— | 2,480*+21.9%— | 1,466—— | 1,714—— | 1,591—— | 2,035*—— | |
| General and administrative | 9,289+35.1%— | 865−23.5%— | 1,446−36.9%— | 1,668−5.3%— | 5,310*+214%— | 1,131−32.5%— | 2,290−4.4%— | 1,762−25.1%— | 1,692*−21.1%— | 1,676—— | 2,395—— | 2,352—— | 2,145*—— | |
| Operating expenses | 13,260−16.3%— | 1,136−57.1%— | 1,809−59.4%— | 2,160−52.8%— | 8,156*+95.5%— | 2,648−15.7%— | 4,457+8.5%— | 4,573+16.0%— | 4,172*−0.2%— | 3,142—— | 4,109—— | 3,943—— | 4,180*—— | |
| Operating income | −13,260—— | −1,136—— | −1,809—— | −2,160—— | −8,156*—— | −2,648—— | −4,457—— | −4,573—— | −4,172*—— | −3,142—— | −4,109—— | −3,943—— | −4,180*—— | |
| Other non-operating income (expense) | — | 87—— | 14—— | −381−1051%— | — | −327−547%— | −772−925%— | 40−70.6%— | 41*−77.1%— | 73—— | 94—— | 137—— | 177*—— | |
| Net income attributable to shareholders | −13,497—— | −1,049—— | −1,795r−1,795—— | −2,541—— | −8,112*—— | −2,975—— | −5,229—— | −4,532—— | −4,131*—— | −3,069—— | −4,015—— | −3,807—— | −4,003*—— | |
| Earnings per share, basic | — | -0.01—— | -0.02—— | -0.23—— | — | -2.98—— | -9.09—— | -9.11r-0.32—— | — | -9.04r-0.32—— | -13.16r-0.47—— | -0.45—— | — | |
| Earnings per share, diluted | — | -0.01—— | -0.02—— | -0.23—— | — | -2.98—— | -9.09—— | -9.11r-0.32—— | — | -9.04r-0.32—— | -13.16r-0.47—— | -0.45—— | — | |
| Shares, weighted average (basic) | 133+13264%— | 133+13264%— | 116+20099%— | 11+2101%— | — | 1.0+194%— | 0.6+88.4%— | 0.5r14−94.1%— | — | 0.3r9.5—— | 0.3r8.5—— | 8.4—— | — | |
| Shares, weighted average (diluted) | 133+13264%— | 133+13264%— | 116+20099%— | 11+2101%— | — | 1.0+194%— | 0.6+88.4%— | 0.5r14−94.1%— | — | 0.3r9.5—— | 0.3r8.5—— | 8.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 26,604—85.2% | 26,604+357%85.2% | 7,554+22.7%63.0% | 1,498−61.5%— | 8,508+47.0%91.4% | 5,826−21.1%85.2% | 6,158−15.7%90.0% | 3,891−60.1%71.9% | 5,787−56.7%78.9% | 7,381—89.6% | 7,302—89.9% | 9,742—89.0% | 13,362—89.5% | |
| Short-term investments | 4,000—12.8% | 4,000—12.8% | 4,000—33.4% | — | — | — | — | — | — | — | — | — | — | |
| Other current assets | 27—0.1% | 27−95.6%0.1% | 28−89.1%0.2% | 683−36.1%— | 803−3.5%8.6% | 613+147%9.0% | 255+36.8%3.7% | 1,070+94.2%19.8% | 832+31.3%11.3% | 249—3.0% | 187—2.3% | 551—5.0% | 633—4.2% | |
| Current assets | — | — | — | 2,181−56.0%— | 9,310+40.7%100% | 6,439−15.6%94.1% | 6,413−14.4%93.8% | 4,961−51.8%91.7% | 6,618−52.7%90.2% | 7,629—92.6% | 7,488—92.2% | 10,293—94.0% | 13,995—93.8% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | — | — | 0.7—0.0% | |
| Right-of-use (leased) assets | — | — | — | — | — | 8.5−92.0%0.1% | 34−73.9%0.5% | 58−61.5%1.1% | 82−52.6%1.1% | 106—1.3% | 129—1.6% | 151—1.4% | 173—1.2% | |
| Non-current assets | — | — | — | — | — | 401−34.3%5.9% | 426−32.7%6.2% | 451−31.3%8.3% | 720−22.4%9.8% | 610—7.4% | 633—7.8% | 656—6.0% | 929—6.2% | |
| Total assets | 31,212—100% | 31,212+356%100% | 11,988+75.3%100% | — | 9,310+26.9%100% | 6,840−17.0%100% | 6,839−15.8%100% | 5,412−50.6%100% | 7,339−50.8%100% | 8,240—100% | 8,122—100% | 10,949—100% | 14,924—100% | |
| Accounts payable | 172—0.5% | 172−75.7%0.5% | 509−17.7%4.2% | 557−57.5%— | 544−37.5%5.8% | 707+27.2%10.3% | 619+48.5%9.0% | 1,311+223%24.2% | 870+8.0%11.9% | 556—6.7% | 417—5.1% | 405—3.7% | 806—5.4% | |
| Current liabilities | — | — | — | 933−64.3%— | 6,159+81.5%66.1% | 2,234+0.1%32.7% | 8,513+342%124% | 2,612+69.9%48.3% | 3,394+22.3%46.2% | 2,232—27.1% | 1,928—23.7% | 1,537—14.0% | 2,774—18.6% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | 4.0—0.0% | 28—0.3% | 51—0.5% | 73—0.5% | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | 4.0—0.0% | 28—0.3% | 51—0.5% | 73—0.5% | |
| Total liabilities | 20,880—66.9% | 20,880—66.9% | 615—5.1% | — | 6,159+81.5%66.1% | — | — | — | 3,394+19.2%46.2% | 2,236—27.1% | 1,956—24.1% | 1,588—14.5% | 2,847—19.1% | |
| Retained earnings | −86,673—−278% | −86,673—−278% | −85,624—−714% | −83,829—— | −81,288—−873% | −73,176—−1070% | −70,201—−1026% | −64,972—−1201% | −60,439—−824% | −56,308—−683% | −53,239—−656% | −49,224—−450% | −45,417—−304% | |
| Shareholders' equity | 10,332—33.1% | 10,332+124%33.1% | 11,373r11,373—94.9% | 1,248−55.4%— | 3,152−20.1%33.9% | 4,606−23.3%67.3% | −1,673−127%−24.5% | 2,800−70.1%51.7% | 3,945−67.3%53.8% | 6,003—72.9% | 6,166—75.9% | 9,361—85.5% | 12,076—80.9% | |
| Total liabilities and equity | 31,212—100% | 31,212+356%100% | 11,988+75.3%100% | 2,181−59.7%— | 9,310+26.9%100% | 6,840−17.0%100% | 6,839−15.8%100% | 5,412−50.6%100% | 7,339−50.8%100% | 8,240—100% | 8,122—100% | 10,949—100% | 14,924—100% | |
| Shares outstanding | 133—— | 133+8015%— | 133+21925%— | 113+606%— | 2.2+405%— | 1.6−83.9%— | 0.6−92.9%— | 16+87.8%— | 0.4r12−94.9%— | 10—— | 8.6—— | 8.5—— | 8.4—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | — | 8.4*−94.4%— | — | 227−5.7%— | 786*+158%— | 151−66.1%— | 181−76.9%— | 241−68.9%— | 304*−59.2%— | 444—— | 783—— | 775—— | 746*—— | |
| Cash from operating activities | −13,565—— | −1,437*—— | −1,928*—— | −7,010—— | −3,191*—— | −2,567*—— | −4,018*—— | −5,047—— | −3,396*—— | −2,513*—— | −2,478*—— | −3,936—— | −2,602*—— | |
| Cash from investing activities | — | 0*—— | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Shares issued | — | 0*−100%— | — | — | −0.2r0*−100%— | 2,339r2,339*−22.0%— | 575*+1354%— | 3,483+936%— | 2,135*—— | 3,000*—— | 40*—— | 336—— | — | |
| Cash from financing activities | — | 20,487*+817%— | — | — | 5,873*+226%— | 2,235*−13.8%— | 6,285*+16411%— | 3,151+897%— | 1,802*—— | 2,592*—— | 38*—— | 316—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Indaptus Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Jeffrey A. Meckler | $2.2 M | $2.1 M | $1.8 M | $12 |
| 2024Jeffrey A. Meckler | $1.2 M | $1.0 M | $950 K | $48 |
| 2023Jeffrey A. Meckler | $1.0 M | $1.1 M | $744 K | $121 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Indaptus Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Change in control 2 · Directors and officers 10 · Material agreement 9 · New debt 2 · Unregistered share sale 7 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K/A | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Shareholder voteResults announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Change in controlDirectors and officers | 8-K | |
| Change in controlShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share saleShareholder vote | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $2 M | Private placement after listing | $2 to $10 million | 20 | options | SEC |
| Jan 2025 | $2 M | Private placement after listing | $2 to $10 million | 16 | equity, options | SEC |
| Jul 2021 | $30 M | Issued in a merger or acquisition | $10 to $50 million | 1 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Indaptus Therapeutics, Inc.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 4 funds hold $70,000automatic update · Jun 30, 2026
4 mutual funds in 1 country hold shares of Indaptus Therapeutics, Inc. worth $70,000, about 0.0% of the company (funds' newest reports, up to 30 June 2026). Since their previous reports 3 funds added shares and 0 sold; on balance they bought $50,000. Share splits are not counted as trading.
How Indaptus Therapeutics, Inc. compares in Biotechnology
- Market cap$513 M · higher than 59% of 726
- Price / book162.9× · lower than 1% of 534
- FCF yield-2.2% · higher than 80% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Indaptus Therapeutics, Inc.🇺🇸 | $513 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Indaptus Therapeutics, Inc.? Verify and update this profile — free
Show Indaptus Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.